Literature DB >> 478651

The sensitivity of gentamicin-resistant gram-negative bacilli to cefotaxime, other cephalosporins and aminoglycosides.

M Stephens, M Potten, A J Bint.   

Abstract

The sensitivities of 80 gentamicin-resistant gram-negative bacilli to cefotaxime, cefuroxime, cefoxitin, cefamandole, cefazolin, tobramycin, netilmicin and amikacin were determined. Amikacin was the most active amino-glycoside. However, the percentage sensitivity to cefotaxime of most of the species was higher than, or equal to any of the other antibiotics tested. Cefotaxime was particulary active against Providencia spp., Serratia spp., Klebsiella spp., and Pseudomonas maltophilia, being 16 to 256 times more active than the next best cephalosporin or cephamycin. Clinical trials of cefotaxime are now required.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 478651     DOI： 10.1007/bf01641308

Source DB:  PubMed          Journal:  Infection        ISSN： 0300-8126            Impact factor:   3.553


  14 in total

1.  Ototoxicity of amikacin.

Authors:  R E Black; W K Lau; R J Weinstein; L S Young; W L Hewitt
Journal:  Antimicrob Agents Chemother       Date:  1976-06       Impact factor: 5.191

2.  Experience with amikacin and colistin in an outbreak of infection by resistant Klebsiella aerogenes.

Authors:  D C Speller; A J Bint; M Stephens
Journal:  J Antimicrob Chemother       Date:  1977-09       Impact factor: 5.790

3.  Experimental evaluation of HR756, a new cephalosporin derivative: pre-clinical study.

Authors:  R Heymès; A Lutz; E Schrinner
Journal:  Infection       Date:  1977       Impact factor: 3.553

4.  Nosocomial infection caused by gentamicin-resistant, streptomycin-sensitive Klebsiella.

Authors:  E R Noriega; R E Leibowitz; A S Richmond; E Rubinstein; S Schaefler; M S Simberkoff; J J Rahal
Journal:  J Infect Dis       Date:  1975-05       Impact factor: 5.226

5.  Amikacin therapy for severe gram-negative sepsis. Emphasis on infections with gentamicin-resistant organisms.

Authors:  F P Tally; T J Louie; W M Weinstein; J G Bartlett; S L Gorbach
Journal:  Ann Intern Med       Date:  1975-10       Impact factor: 25.391

6.  In vitro study of netilmicin compared with other aminoglycosides.

Authors:  K P Fu; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1976-09       Impact factor: 5.191

7.  Tobramycin, amikacin, sissomicin, and gentamicin resistant Gram-negative rods.

Authors:  F A Drasar; W Farrell; J Maskell; J D Williams
Journal:  Br Med J       Date:  1976-11-27

8.  Controlled comparison of amikacin and gentamicin.

Authors:  C R Smith; K L Baughman; C Q Edwards; J F Rogers; P S Lietman
Journal:  N Engl J Med       Date:  1977-02-17       Impact factor: 91.245

9.  Comparison of the antibacterial activity of nine cephalosporins against Enterobacteriaceae and nonfermentative gram-negative bacilli.

Authors:  L Verbist
Journal:  Antimicrob Agents Chemother       Date:  1976-10       Impact factor: 5.191

10.  Newer aminoglycosides--amikacin and tobramycin: an in-vitro comparison with kanamycin and gentamicin.

Authors:  A V Reynolds; J M Hamilton-Miller; W Brumfitt
Journal:  Br Med J       Date:  1974-09-28
View more
  5 in total

1.  Bone and joint infections caused by gram-positive bacteria: treatment with cefotaxime.

Authors:  J LeFrock; J Mader; B Smith; B Carr
Journal:  Infection       Date:  1985       Impact factor: 3.553

2.  The effect of N-formimidoyl thienamycin, ceftazidime, cefotiam, ceftriaxone and cefotaxime on non-fermentative Gram-negative rods, Aeromonas, Plesiomonas and Enterobacter agglomerans.

Authors:  A von Graevenitz; C Bucher
Journal:  Infection       Date:  1982 Sep-Oct       Impact factor: 3.553

3.  Clinical evaluation of cefotaxime for therapy of lower respiratory tract infections.

Authors:  C J Schleupner; J C Engle
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191

4.  Aminoglycoside-resistant gram-negative bacilli in a community hospital: comparative in vitro activity of cefotaxime, moxalactam, cefoperazone, and piperacillin.

Authors:  C R Magnussen; M T Sammartino; K D Ernest
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

Review 5.  Cefotaxime. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-03       Impact factor: 9.546
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.